Advertisement

Topics

Combining Implantation of Glaukos iStent inject® Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study

07:00 EDT 21 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
After 18 Months of Follow-up, Mean IOP Declined 35% to 12.9 mm Hg Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and proce...

Other Sources for this Article

Glaukos Corporation
Media Contact:
Cassandra Dump
(619) 971-1887
cassy@pascalecommunications.com
or
Investor Contact:
Sheree Aronson
VP, Investor Relations
(949) 367-9600 ext 371
saronson@glaukos.com

NEXT ARTICLE

More From BioPortfolio on "Combining Implantation of Glaukos iStent inject® Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...